

Global Cough Syrup Market Report and Forecast 2023-2031

Market Report | 2023-04-18 | 147 pages | EMR Inc.

AVAILABLE LICENSES:

- Single User License \$5999.00
- Five User License \$7999.00
- Corporate License \$9999.00

Report description:

Global Cough Syrup Market Report and Forecast 2023-2031

Global Cough Syrup Market Outlook

The global cough syrup market attained a value of about USD 5,994.22 million in 2022. The market is expected to grow at a CAGR of 3.8% during the forecast period of 2023-2031 to attain nearly USD 8,398.12 million by 2031. The market growth is likely to be aided by the growing government investment during the forecast period of 2023-2031.

Cough Syrup Market: Introduction

Cough syrup is a type of medicine that is used to treat coughs, either dry or productive (coughs that produce mucus). It is typically a liquid medication that is taken orally, and it contains ingredients that can help to alleviate coughing and soothe the throat.

The active ingredients in cough syrup can vary, but they may include cough suppressants, expectorants, and/or antihistamines. Cough suppressants are used to suppress the cough reflex, while expectorants are used to thin mucus and make it easier to cough up. Antihistamines may be included to help reduce inflammation and irritation in the throat.

Cough syrup can be used to treat various types of coughs, including those associated with the common cold, flu, and bronchitis. It can also be used to treat coughs caused by allergies, asthma, and other respiratory conditions. Additionally, some cough syrups may contain other ingredients such as pain relievers or fever reducers to help alleviate other symptoms associated with coughs. It is important to follow the recommended dosage and instructions when taking cough syrup, as overuse or misuse can lead to side effects. Additionally, cough syrup may not be appropriate for everyone, particularly those with certain medical conditions or who are taking other medications. It is always best to speak with a healthcare provider before taking any new medication.

Cough Syrup Market Segmentations

Market Breakup by Product Type

-□Expectorants

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- Cough Suppressants
- Combination Medications
- Others

Market Breakup by Population Type

- Paediatric
- Adults

Market Breakup by Distribution Channel

- Hospital Pharmacy
- Retail Pharmacy
- Online Channel
- Public Channel

Cough Syrup Market Breakup by Region

- North America
- United States of America
- Canada
- Europe
- United Kingdom
- Germany
- France
- Italy
- Others
- Asia Pacific
- China
- Japan
- India
- ASEAN
- Australia
- Others
- Latin America
- Brazil
- Argentina
- Mexico
- Others
- Middle East and Africa
- Saudi Arabia
- United Arab Emirates
- Nigeria
- South Africa
- Others

Cough Syrup Market Scenario

The cough syrup market has been driven by several key factors, including the increasing prevalence of respiratory illnesses, the growing awareness of the benefits of cough syrups, and the availability of over-the-counter (OTC) medications. In recent years, the incidence of respiratory illnesses such as the common cold, flu, and asthma has been on the rise, driving demand for cough syrups as an effective treatment option. Additionally, the growing awareness of the benefits of cough syrup, including its ability to provide relief from coughing and soothe the throat, has led to an increased demand for the product.

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

The availability of cough syrup as an OTC medication has also contributed to its popularity. Consumers can easily purchase cough syrup without a prescription, making it a convenient option for those who need quick relief from coughing. The development of new formulations and flavours of cough syrup has also driven market growth, as manufacturers seek to offer products that are more appealing and easier to take.

Moreover, the increasing adoption of online retail channels for the sale of cough syrup and other OTC medicines has further driven market growth. The availability of online platforms has made it easier for consumers to purchase cough syrup from the comfort of their homes. The trend of self-medication and growing healthcare awareness among people is expected to fuel the demand for cough syrup in the coming years. As a result, the cough syrup market is expected to continue growing in the foreseeable future.

Key Players in the Global Cough Syrup Market

The report gives an in-depth analysis of the key players involved in the cough syrup market, sponsors manufacturing the drugs, and putting them through trials to get FDA approvals. The companies included in the market are as follows:

- [] Acella Pharmaceuticals LLC
- [] Bayer AG
- [] GlaxoSmithKline PLC
- [] Johnson & Johnson
- [] Pfizer Inc.
- [] Prestige Consumer Healthcare Inc.
- [] Reckitt Benckiser Group PLC
- [] Sanofi
- [] Sun Pharmaceutical Industries Limited
- [] The Procter & Gamble Company

Table of Contents:

- 1 Preface
 - 1.1 Objectives of the Study
 - 1.2 Key Assumptions
 - 1.3 Report Coverage - Key Segmentation and Scope
 - 1.4 Research Methodology
- 2 Executive Summary
- 3 Global Cough Syrup Market Overview
 - 3.1 Global Cough Syrup Market Historical Value (2016-2022)
 - 3.2 Global Cough Syrup Market Forecast Value (2023-2031)
- 4 Global Cough Syrup Market Landscape
 - 4.1 Global Cough Syrup Developers Landscape
 - 4.1.1 Analysis by Year of Establishment
 - 4.1.2 Analysis by Company Size
 - 4.1.3 Analysis by Region
 - 4.2 Global Cough Syrup Product Landscape
 - 4.2.1 Analysis by Product Type
 - 4.2.2 Analysis by Drug Type
 - 4.2.3 Analysis by Population type
 - 4.2.4 Analysis by Therapy Type
 - 4.2.5 Analysis by Distribution Channel

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 5 Global Cough Syrup Market Dynamics
 - 5.1 Market Drivers and Constraints
 - 5.2 SWOT Analysis
 - 5.3 Porter's Five Forces Model
 - 5.4 Key Demand Indicators
 - 5.5 Key Price Indicators
 - 5.6 Industry Events, Initiatives, and Trends
 - 5.7 Value Chain Analysis
- 6 Global Cough Syrup Market Segmentation
 - 6.1 Global Cough Syrup Market by Product Type
 - 6.1.1 Market Overview
 - 6.1.2 Expectorants
 - 6.1.3 Cough Suppressants
 - 6.1.4 Combination Medications
 - 6.1.5 Others
 - 6.2 Global Cough Syrup Market by Population Type
 - 6.2.1 Market Overview
 - 6.2.2 Pediatric
 - 6.2.3 Adults
 - 6.3 Global Cough Syrup Market by Distribution Channel
 - 6.3.1 Market Overview
 - 6.3.2 Hospital Pharmacy
 - 6.3.3 Retail Pharmacy
 - 6.3.4 Online Channel
 - 6.3.5 Public Channel
 - 6.4 Global Cough Syrup Market by Region
 - 6.4.1 Market Overview
 - 6.4.2 North America
 - 6.4.3 Europe
 - 6.4.4 Asia Pacific
 - 6.4.5 Latin America
 - 6.4.6 Middle East and Africa
- 7 North America Cough Syrup Market
 - 7.1 Market Share by Country
 - 7.2 United States of America
 - 7.3 Canada
- 8 Europe Cough Syrup Market
 - 8.1 Market Share by Country
 - 8.2 United Kingdom
 - 8.3 Germany
 - 8.4 France
 - 8.5 Italy
 - 8.6 Others
- 9 Asia Pacific Cough Syrup Market
 - 9.1 Market Share by Country
 - 9.2 China
 - 9.3 Japan

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 9.4 India
- 9.5 ASEAN
- 9.6 Australia
- 9.7 Others
- 10 Latin America Cough Syrup Market
 - 10.1 Market Share by Country
 - 10.2 Brazil
 - 10.3 Argentina
 - 10.4 Mexico
 - 10.5 Others
- 11 Middle East and Africa Cough Syrup Market
 - 11.1 Market Share by Country
 - 11.2 Saudi Arabia
 - 11.3 United Arab Emirates
 - 11.4 Nigeria
 - 11.5 South Africa
 - 11.6 Others
- 12 Patent Analysis
 - 12.1 Analysis by Type of Patent
 - 12.2 Analysis by Publication Year
 - 12.3 Analysis by Issuing Authority
 - 12.4 Analysis by Patent Age
 - 12.5 Analysis by CPC Analysis
 - 12.6 Analysis by Patent Valuation
 - 12.7 Analysis by Key Players
- 13 Grants Analysis
 - 13.1 Analysis by year
 - 13.2 Analysis by Amount Awarded
 - 13.3 Analysis by Issuing Authority
 - 13.4 Analysis by Grant Application
 - 13.5 Analysis by Funding Institute
 - 13.6 Analysis by NIH Departments
 - 13.7 Analysis by Recipient Organization
- 14 Funding Analysis
 - 14.1 Analysis by Funding Instances
 - 14.2 Analysis by Type of Funding
 - 14.3 Analysis by Funding Amount
 - 14.4 Analysis by Leading Players
 - 14.5 Analysis by Leading Investors
 - 14.6 Analysis by Geography
- 15 Partnership and Collaborations Analysis
 - 15.1 Analysis by Partnership Instances
 - 15.2 Analysis by Type of Partnership
 - 15.3 Analysis by Leading Players
 - 15.4 Analysis by Geography
- 16 Regulatory Framework
 - 16.1 Regulatory Overview

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 16.1.1 US FDA
- 16.1.2 EU EMA
- 16.1.3 INDIA CDSCO
- 16.1.4 JAPAN PMDA
- 16.1.5 Others
- 17 Supplier Landscape
 - 17.1 Acella Pharmaceuticals LLC
 - 17.1.1 Financial Analysis
 - 17.1.2 Product Portfolio
 - 17.1.3 Demographic Reach and Achievements
 - 17.1.4 Mergers and Acquisitions
 - 17.1.5 Certifications
 - 17.2 Bayer AG
 - 17.2.1 Financial Analysis
 - 17.2.2 Product Portfolio
 - 17.2.3 Demographic Reach and Achievements
 - 17.2.4 Mergers and Acquisitions
 - 17.2.5 Certifications
 - 17.3 GlaxoSmithKline PLC
 - 17.3.1 Financial Analysis
 - 17.3.2 Product Portfolio
 - 17.3.3 Demographic Reach and Achievements
 - 17.3.4 Mergers and Acquisitions
 - 17.3.5 Certifications
 - 17.4 Johnson & Johnson
 - 17.4.1 Financial Analysis
 - 17.4.2 Product Portfolio
 - 17.4.3 Demographic Reach and Achievements
 - 17.4.4 Mergers and Acquisitions
 - 17.4.5 Certifications
 - 17.5 Pfizer Inc.
 - 17.5.1 Financial Analysis
 - 17.5.2 Product Portfolio
 - 17.5.3 Demographic Reach and Achievements
 - 17.5.4 Mergers and Acquisitions
 - 17.5.5 Certifications
 - 17.6 Prestige Consumer Healthcare Inc.
 - 17.6.1 Financial Analysis
 - 17.6.2 Product Portfolio
 - 17.6.3 Demographic Reach and Achievements
 - 17.6.4 Mergers and Acquisitions
 - 17.6.5 Certifications
 - 17.7 Reckitt Benckiser Group PLC
 - 17.7.1 Financial Analysis
 - 17.7.2 Product Portfolio
 - 17.7.3 Demographic Reach and Achievements
 - 17.7.4 Mergers and Acquisitions

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 17.7.5 Certifications
- 17.8 Sanofi
 - 17.8.1 Financial Analysis
 - 17.8.2 Product Portfolio
 - 17.8.3 Demographic Reach and Achievements
 - 17.8.4 Mergers and Acquisitions
 - 17.8.5 Certifications
- 17.9 Sun Pharmaceutical Industries Limited
 - 17.9.1 Financial Analysis
 - 17.9.2 Product Portfolio
 - 17.9.3 Demographic Reach and Achievements
 - 17.9.4 Mergers and Acquisitions
 - 17.9.5 Certifications
- 17.10 The Procter & Gamble Company
 - 17.10.1 Financial Analysis
 - 17.10.2 Product Portfolio
 - 17.10.3 Demographic Reach and Achievements
 - 17.10.4 Mergers and Acquisitions
 - 17.10.5 Certifications
- 18 Global Cough Syrup Market - Distribution Model (Additional Insight)
 - 18.1 Overview
 - 18.2 Potential Distributors
 - 18.3 Key Parameters for Distribution Partner Assessment
- 19 Key Opinion Leaders (KOL) Insights (Additional Insight)
- 20 Company Competitiveness Analysis (Additional Insight)
 - 20.1 Very Small Companies
 - 20.2 Small Companies
 - 20.3 Mid-Sized Companies
 - 20.4 Large Companies
 - 20.5 Very Large Companies
- 21 Payment Methods (Additional Insight)
 - 21.1 Government Funded
 - 21.2 Private Insurance
 - 21.3 Out-of-Pocket

Global Cough Syrup Market Report and Forecast 2023-2031

Market Report | 2023-04-18 | 147 pages | EMR Inc.

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User License	\$5999.00
	Five User License	\$7999.00
	Corporate License	\$9999.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

☐ ** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2025-06-13"/>
		Signature	<input type="text"/>

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com